Cancer is a genetic disease. It is caused by changes in the genes that control how cells grow, divide, and die. But “genetic” doesn’t necessarily mean “inherited.” Only about 5% to 10% of all cancers are caused by mutations passed down from a parent. The vast majority arise from DNA damage that accumulates in individual cells over the course of a person’s life.
What “Genetic Disease” Actually Means
When scientists call cancer a genetic disease, they mean it begins with alterations to DNA. These alterations disrupt the normal instructions that tell a cell when to grow, when to stop growing, and when to self-destruct if something goes wrong. A healthy cell doesn’t become cancerous from a single DNA change. Multiple genetic errors need to pile up before a cell breaks free of its normal controls and starts multiplying without restraint.
Those DNA changes can happen in three ways. First, random copying mistakes occur every time a cell divides. Your body makes billions of new cells daily, and the machinery that copies DNA occasionally gets a letter wrong. Second, environmental exposures physically damage DNA. Chemicals in tobacco smoke, ultraviolet radiation from the sun, and certain viruses like HPV can all alter the genetic code. Third, some DNA changes are inherited, passed from parent to child at conception.
Three Types of Genes Involved
Not every gene matters equally in cancer. Three categories play the biggest roles.
- Growth-promoting genes (oncogenes): These start as normal genes called proto-oncogenes that help cells grow and divide on schedule. When they mutate or get duplicated too many times, they become permanently switched on, like a gas pedal stuck to the floor. The cell keeps dividing when it shouldn’t.
- Growth-suppressing genes (tumor suppressors): These act as the brake pedal, slowing cell division or stopping it entirely. When mutations disable them, the cell loses its ability to pump the brakes, and growth continues unchecked.
- DNA repair genes: These fix the copying errors that naturally occur during cell division. When repair genes themselves are damaged, mistakes in other genes go uncorrected and accumulate faster, accelerating the path toward cancer.
A tumor typically carries mutations in several of these gene types at once. That combination of a stuck accelerator, broken brakes, and a disabled repair system is what makes cancer cells so aggressive.
Inherited Mutations vs. Acquired Mutations
The distinction between inherited and acquired mutations is one of the most important things to understand about cancer genetics. Inherited (germline) mutations are present in every cell of your body from birth because they were passed down from a parent. Acquired (somatic) mutations happen in a single cell at some point during your life and are not passed to your children. Somatic mutations are by far the more common cause, responsible for roughly 90% to 95% of all cancers.
Having an inherited mutation doesn’t guarantee you’ll develop cancer. It means you start life one step further down the path. Your cells already carry one hit, so fewer additional mutations are needed before a cell turns malignant. This is why hereditary cancers often appear at younger ages than cancers driven entirely by acquired mutations.
How Environmental Damage Changes DNA
Environmental carcinogens don’t just vaguely “cause cancer.” They physically alter the DNA molecule. Tobacco smoke, for example, contains a compound called benzo[a]pyrene that gets chemically activated inside the body and binds directly to DNA, forming what scientists call DNA adducts. These adducts are like roadblocks that prevent the cell from reading its genetic instructions correctly. If the cell’s repair system can’t fix the damage, the result is a permanent mutation. Benzo[a]pyrene has been found to preferentially bind to critical spots on the p53 gene, one of the most important tumor suppressors in the body.
UV radiation works differently but produces a similar result: it causes neighboring DNA letters to fuse together, creating errors that the cell may copy incorrectly during its next division. Each of these individual mutations is small, but over years and decades of exposure, they add up.
Why Cancer Risk Rises With Age
Somatic mutations accumulate with age in virtually all tissues. Every time a cell divides, there’s a small chance of a copying error, and those errors build up over a lifetime. By the time you’re in your 60s or 70s, your cells have been through decades of division, environmental exposure, and imperfect repair. This is the primary reason cancer is overwhelmingly a disease of older adults.
Recent advances in DNA sequencing have revealed that even apparently healthy tissues in older people carry clusters of cells with cancer-associated mutations. In blood, this phenomenon is called clonal hematopoiesis: small populations of cells carrying the same mutation expand over time. Clonal hematopoiesis correlates with higher risk of blood cancers, cardiovascular disease, and overall mortality, though researchers are still working out whether the specific mutations drive those risks or simply reflect broader genomic wear and tear.
Genes Can Be Silenced Without Mutating
Not all genetic disruption involves changes to the DNA sequence itself. Cancer cells frequently use a second trick: they silence tumor suppressor genes by altering how the DNA is packaged and read, without changing the underlying code. This process, called epigenetic silencing, works by attaching small chemical tags to DNA or to the proteins that DNA wraps around. These tags effectively lock the gene shut so the cell can no longer produce the protective protein it encodes.
The result is functionally identical to a mutation. A tumor suppressor gene that’s been silenced epigenetically is just as inactive as one that’s been physically damaged. Many cancers use a combination of both strategies, knocking out some protective genes through mutations and others through epigenetic silencing.
Well-Known Inherited Cancer Syndromes
The best-studied inherited cancer genes are BRCA1 and BRCA2. Women who carry a harmful change in either gene face dramatically higher lifetime risks of breast and ovarian cancer. More than 60% of women with a BRCA1 or BRCA2 mutation will develop breast cancer, compared with about 13% of women in the general population. For ovarian cancer, the numbers are equally striking: 39% to 58% of BRCA1 carriers and 13% to 29% of BRCA2 carriers will develop the disease, versus about 1.1% of the general population.
These genes affect men too. Men with BRCA2 mutations have a 19% to 61% chance of developing prostate cancer by age 80, compared with about 10.6% in the general population. Both mutations also raise the risk of pancreatic cancer to roughly 5% to 10%, compared with a baseline of 1.7%.
BRCA mutations aren’t the only hereditary cancer syndromes. Lynch syndrome, caused by inherited defects in DNA repair genes, substantially raises the risk of colorectal, endometrial, and several other cancers. Dozens of other inherited syndromes exist, each linked to specific gene mutations and cancer types.
How Genetic Knowledge Shapes Treatment
Understanding cancer as a genetic disease has transformed treatment. Doctors now routinely sequence the DNA of tumors to look for specific mutations that can be targeted with precision therapies. In advanced lung cancer, for instance, patients whose tumors carry certain mutations in growth-signaling genes can receive targeted drugs that block those specific signals. These targeted treatments improve survival compared with traditional chemotherapy.
Genetic testing also guides prevention. People who learn they carry a BRCA mutation or Lynch syndrome can pursue earlier and more frequent screening, and in some cases preventive surgery, to catch or prevent cancer before it develops. For metastatic prostate cancer, clinical guidelines now recommend that all patients undergo genetic testing, both to identify inherited risk that could affect family members and to find tumor-specific mutations that might respond to targeted therapies.
The genetic nature of cancer also explains why it’s so difficult to cure. Because tumors accumulate new mutations as they grow, they can evolve resistance to treatments. A drug that targets one mutation may work for months or years, only for the tumor to develop a second mutation that bypasses the blockade. This is why many advanced cancers are treated with combinations of therapies, each aimed at a different genetic vulnerability.